Αρχική World News Zanidatamab Plus Chemotherapy Prolongs PFS Over Trastuzumab Plus Chemotherapy in Patients with... World News Zanidatamab Plus Chemotherapy Prolongs PFS Over Trastuzumab Plus Chemotherapy in Patients with HER2-positive Advanced Gastro-Oesophageal Adenocarcinoma Από Ogkologos - 1 Ιουνίου, 2026 292 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the HERIZON-GEA-01 study Source ΠΑΡΟΜΟΙΑ ΑΡΘΡΑΠΕΡΙΣΣΟΤΕΡΑ ΑΠΟ ΤΟΝ ΔΗΜΙΟΥΡΓΟ Ahead of the Special European Council Meeting on 26-27 November, ESMO Calls on EU Governments to Continue Support for the Cancer Mission European Parliament backs key priorities advocated by ESMO for cancer research and innovation FDA approves giredestrant in combination with everolimus for ER-positive, HER2-negative, ESR1-mutated locally advanced or metastatic breast cancer MOST POPULAR EMA Recommends Extension of Indications for Nivolumab and Ipilimumab 25 Σεπτεμβρίου, 2020 Additional 5 Years of AI Treatment Reduces Distant Recurrence Rates Among... 25 Αυγούστου, 2025 Breastfeeding Duration Could Influence Breast Cancer Risk, Study Shows 27 Σεπτεμβρίου, 2019 EMA Recommends Extension of Therapeutic Indications for Trifluridine/Tipiracil 7 Ιουλίου, 2023 Φόρτωση περισσοτέρων HOT NEWS Weak Immunogenicity in Patients with Cancer After First Dose of mRNA-based... How we can reduce cancer risk in inflammatory bowel disease patients... Caregivers Empower the Next Generation of Cancer Care Έγκριση νέας επικουρικής θεραπείας για τον θετικά πρώιμο καρκίνο του μαστού